Tumor

The most recent findings related to tumors are available from Neurosurgery Watch.

TU

Two Phase III trials do not show improved GBM survival with addition of bevacizumab

March 29, 2014
Tumor
By: 
Nader Sanai, MD

The New England Journal of Medicine (Feb ‘14) reported results from two randomized, double-blind, placebo-controlled Phase III trials testing addition of bevacizumab (BEV) to standard radiation + temozolomide therapy for newly-diagnosed glioblastoma (GBM): Radiation Therapy Oncology Group 0825 and ‘Avastin...

SF
TU

Predicting Overall Survival for Patients After Radiosurgery for Brain Metastases

February 3, 2014
Stereotactic & Functional, Tumor
By: 
Gavin P. Dunn, MD PhD
Gabriel Zada, MD
Source: 
Journal of Neurosurgery

Difficulties in predicting survival for brain metastasis patients is underappreciated and has ramifications for cost-effective care. Kondziolka et al. assessed the ability of clinicians to predict survival in 150 cancer patients undergoing stereotactic radiosurgery for brain metastases from 2009-11. Clinicians...

SF
TU

Resection Bed Radiosurgery Improves Local Control for Brain Metastases

February 3, 2014
Stereotactic & Functional, Tumor
By: 
Jonathan Sherman, MD
J. Bradley Elder, MD
Source: 
http://journals.lww.com/neurosurgery/Abstract/2013/12000/Predicting_Tumor_Contro...

Current management of brain metastases frequently involves stereotactic radiosurgery (SRS) and/or whole brain radiation therapy (WBRT) after surgery. This study examines factors associated with SRS to the surgical bed after brain metastasis resection. Overall, 86% of 120 patients achieved local...

TU

Dose-Dense Temozolomide Is Not Superior to Standard Dose Temozolomide for Glioblastoma

January 2, 2014
Tumor
By: 
Clark C. Chen, MD PhD
Source: 
PubMed

Escalating temozolomide dose regimen beyond that used in standard therapy, termed the dose dense regimen, has been proposed as a means to functional deplete MGMT and improve temozolomide efficacy in the management of glioblastoma. This randomized control trial evaluated 883...

SF
TU

Radiosurgical Management of Non-Functional Pituitary Adenomas

October 1, 2013
Stereotactic & Functional, Tumor
By: 
Gavin P. Dunn, MD PhD
Gabriel Zada, MD
Source: 
Journal of Neurosurgery

The North American Gamma Knife Consortium reported outcomes following gamma knife radiosurgery (GKRS) for nonfunctioning pituitary adenomas in 512 patients (93.6% with prior surgical resection) with median 36 months followup (range 1-223 months) and median tumor margin dose of 16...

TU

Does Prior Microsurgery Improve or Worsen Stereotactic Radiosurgery Outcome for Cavernous Sinus Meningiomas?

October 1, 2013
Tumor
By: 
Jonathan Sherman, MD
J. Bradley Elder, MD
Source: 
Neurosurgery

Cavernous sinus meningiomas are increasingly treated with stereotactic radiosurgery alone or combined with surgical resection of tumor external to the cavernous sinus. From the University of Pittsburgh, Kano et al reported one of the largest series of cavernous sinus meningiomas...

SP
TU

Risk Factors for Vertebral Compression Fractures After Stereotactic Radiotherapy for Spinal Metastases

October 1, 2013
Spine, Tumor
By: 
Clark C. Chen, MD PhD
Joseph D. Ciacci, MD
Source: 
Journal of Clinical Oncology

Vertebral compression fractures (VCF) are an adverse event after stereotactic body radiotherapy (SBRT) or radiosurgery for spinal metastases. A recent Journal of Clinical Oncology report retrospectively reviewed the SBRT experience at MD Anderson Cancer Center, Cleveland Clinic, and University of...

TU

Maximizing Resection Correlate with Positive Prognosis for Adult WHO Grade II Gliomas at Diagnosis and Recurrence

July 10, 2013
Tumor
By: 
John S. Kuo, MD PhD
Source: 
Journal of Neurosurgery

The largest modern series of 1097 WHO Grade II gliomas (with MRI-verified tumor sizes) collected by the multi-center French Glioma Research Group from January 1985 to December 2007 (mean 7.4 year follow-up) was reported in Journal of Neurosurgery (June 2013)....

Pages